FindTrial
Sign In

Rivaroxaban placebo

DRUG3 trials

Sponsors

Bayer

Conditions

Atrial FibrillationPrevention & ControlVenous Thromboembolism

Phase 3

Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
CompletedNCT00494871
BayerAtrial Fibrillation
Start: 2007-06-30End: 2010-01-31Updated: 2015-04-20
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
CompletedNCT00571649
BayerVenous Thromboembolism
Start: 2007-12-31End: 2010-11-30Updated: 2016-09-15
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
CompletedNCT01776424
BayerPrevention & Control
Start: 2013-02-28End: 2021-06-15Updated: 2022-11-28

Related Papers

Comparison of total event analysis and first event analysis in relation to heterogeneity in cardiovascular trials.
2025-06-09
Improving analysis of cognitive outcomes in cardiovascular trials using different statistical approaches.
2024-10-02
Health-related quality of life with rivaroxaban plus aspirin vs. aspirin alone in chronic stable cardiovascular disease: Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial
European Heart Journal Open2024-08-311 citations
Results of the COMPASS Trial Analyzed Using Win Ratio Compared With Conventional Analytic Approaches.
2024-07-144 citations
Impact of Frailty on the Benefits of Dual Pathway Inhibition for the Secondary Prevention of Cardiovascular Events in the COMPASS Randomised Trial.
2024-06-226 citations
The Effects of Pantoprazole on Kidney Outcomes
Journal of the American Society of Nephrology2024-04-119 citations
The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective.
2023-12-286 citations
The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial.
2023-08-0110 citations
Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial.
2023-01-147 citations
Health status and cognitive function for risk stratification in chronic coronary and peripheral artery disease
European Journal of Preventive Cardiology2022-11-2810 citations
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events
JAMA Network Open2022-11-2112 citations
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials
Circulation2022-04-078 citations
Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER
Journal of the American Heart Association2021-11-1012 citations
Optimum Treatment Strategy in Chronic Coronary Syndromes: the New Trials vs the Current Guidelines
Rational Pharmacotherapy in Cardiology2021-11-031 citations
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease.
2021-07-0131 citations
Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery
JAMA Cardiology2021-06-1662 citations
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease
Heart2021-05-219 citations
Risk stratification of cardiovascular complications using CHA<sub>2</sub>DS<sub>2</sub>-VASc and CHADS<sub>2</sub> scores in chronic atherosclerotic cardiovascular disease.
2021-05-035 citations
Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients
Journal of the American Heart Association2021-02-1542 citations
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.
2021-02-0112 citations

29 more papers not shown